Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

作者: Benjamin D. Smith , Grace L. Smith , Arti Hurria , Gabriel N. Hortobagyi , Thomas A. Buchholz

DOI: 10.1200/JCO.2008.20.8983

关键词:

摘要: Purpose By 2030, the United States' population will increase to approximately 365 million, including 72 million older adults (age ≥ 65 years) and 157 million minority individuals. Although cancer incidence varies by age and race, the impact of demographic changes on cancer incidence has not been fully characterized. We sought to estimate the number of cancer patients diagnosed in the United States through 2030 by age and race. Methods Current demographic-specific cancer incidence rates were calculated using the Surveillance Epidemiology and End Results database. Population projections from the Census Bureau were used to project future cancer incidence through 2030. Results From 2010 to 2030, the total projected cancer incidence will increase by approximately 45%, from 1.6 million in 2010 to 2.3 million in 2030. This increase is driven by cancer diagnosed in older adults and minorities. A 67% increase in cancer incidence is anticipated for older adults, compared with an 11% increase for younger adults. A 99% increase is anticipated for minorities, compared with a 31% increase for whites. From 2010 to 2030, the percentage of all cancers diagnosed in older adults will increase from 61% to 70%, and the percentage of all cancers diagnosed in minorities will increase from 21% to 28%. Conclusion Demographic changes in the United States will result in a marked increase in the number of cancer diagnoses over the next 20 years. Continued efforts are needed to improve cancer care for older adults and minorities.

参考文章(26)
Great Britain. Scottish Office, Census of population H.M.S.O. ,(1988)
Karen M. Freund, Tracy A. Battaglia, Elizabeth Calhoun, Donald J. Dudley, Kevin Fiscella, Electra Paskett, Peter C. Raich, Richard G. Roetzheim, , National Cancer Institute Patient Navigation Research Program Cancer. ,vol. 113, pp. 3391- 3399 ,(2008) , 10.1002/CNCR.23960
Hervé Dombret, Emmanuel Raffoux, Claude Gardin, Acute myeloid leukemia in the elderly. Seminars in Oncology. ,vol. 35, pp. 430- 438 ,(2008) , 10.1053/J.SEMINONCOL.2008.04.013
Eileen F. Dunne, S. Deblina Datta, Lauri E. Markowitz, A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the US Cancer. ,vol. 113, pp. 2995- 3003 ,(2008) , 10.1002/CNCR.23763
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M. J. Thun, Cancer statistics, 2008. CA: A Cancer Journal for Clinicians. ,vol. 58, pp. 71- 96 ,(2008) , 10.3322/CA.2007.0010
Thierry Gorlia, Martin J van den Bent, Monika E Hegi, René O Mirimanoff, Michael Weller, J Gregory Cairncross, Elizabeth Eisenhauer, Karl Belanger, Alba A Brandes, Anouk Allgeier, Denis Lacombe, Roger Stupp, Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncology. ,vol. 9, pp. 29- 38 ,(2008) , 10.1016/S1470-2045(07)70384-4
Cary P. Gross, Benjamin D. Smith, Elizabeth Wolf, Martin Andersen, Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. ,vol. 112, pp. 900- 908 ,(2008) , 10.1002/CNCR.23228
Harry Bartelink, Jean-Claude Horiot, Philip Poortmans, Henk Struikmans, Walter Van den Bogaert, Isabelle Barillot, Alain Fourquet, Jacques Borger, Jos Jager, Willem Hoogenraad, Laurence Collette, Marianne Pierart, Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. The New England Journal of Medicine. ,vol. 345, pp. 1378- 1387 ,(2001) , 10.1056/NEJMOA010874